A Phase III clinical trial to evaluate the safety and efficacy of Trasylol® (aprotinin injection) in reducing blood loss and the need for transfusion in adult patients undergoing elective spinal fusion surgery has been initiated. The effect of Trasylol use involves a reduction of inflammatory response to surgery, reduced bleeding and decreased re-exploration for bleeding, which translates into a decreased need for allogeneic (blood donated from another individual) blood transfusions.
OrthopaedicLIST.com is a list of products and services. Every effort is made to keep this listing as accurate and current as possible. Companies and individuals are encouraged to notify us of errors and omissions. We will respond to such messages of correction in a timely fashion, as our workload permits.
We are non-judgmental of products listed. We are not in the business of evaluating products. We have not evaluated these products. We make no representations as to the quality, effectiveness, suitability or appropriateness of any of the products listed.
As an important component of the service function of OrthopaedicLIST.com, some products continue to be listed that are no longer manufactured and may not be available. We will identify them as such when possible. This allows users to find special instruments and/or components for removal, modification, and/or revision of those products.